

Remarks

Prompt and favorable consideration of this Preliminary Amendment is respectfully requested. Claim 2 has been canceled, and claims 12-46 have been added. Upon entry of the foregoing Preliminary Amendment, claims 1 and 3-46 will be subject to examination in the application, with claims 1, 12, 14, 15, 31 and 39 being the independent claims.

Applicants have amended the specification to cross-reference related Application Nos. 09/560,887, 09/224,953 and 09/032,777.

In addition, the application has been amended to add new claims 12-46. These claims were added in the parent application to copy claims from issued U.S. patents. More specifically, new claims 12-27 and 29-30 correspond to claims 1-6, 8-14, 16-19, 22-31 and 38 of U.S. Patent No. 6,001,852, issued on December 14, 1999; and new claims 31-46 correspond to claims 1-9 and 16 of U.S. Patent No. 5,994,323, issued on November 30, 1999; and to claims 21-29 and 36 of U.S. Patent No. 5,980,914, issued on November 9, 1999.

Support for claims 12-46 can be found, *inter alia*, as described in the following table:

Claim	Location of Support in Specification
12	page 1, lines 7-16; page 5, line 21 to page 6, line 20; page 7, lines 24-25; page 18, lines 4-6; page 19, lines 5-6
13	page 3, lines 23-25 and 27-29; page 5, lines 17-20; page 9, lines 3-12.
14	page 6, lines 1-20; page 16, line 14 to page 18, line 6.

Claim	Location of Support in Specification
15	page 3, lines 9-12 and 26-27; page 8, lines 20-26; page 9, lines 1-2 and 11-12; page 19, lines 7-8.
16	page 8, lines 20-26.
17	page 3, lines 23-25 and 27-29; page 5, lines 17-20; page 9, lines 3-12.
18 & 19	page 3, lines 23-25.
20	page 3, lines 23-25 and 27-29; page 5, lines 17-20; page 9, lines 3-12.
21	page 12, line 29 to page 13, line 2; page 18, lines 4-6.
22	page 3, lines 13-15; page 8, lines 6-12, 18-19 and 27-28; page 12, lines 17-19.
23	page 3, lines 11-12 and 22-27; page 19, lines 17-19.
24	page 3, lines 27-29; page 19, lines 17-19.
25	page 4, lines 1-2; page 19, lines 24-25.
26	page 3, lines 26-27; page 10, line 22 to page 11, line 22; page 19, lines 11-12.
27	page 3, lines 26-27; page 12, lines 1-11; page 19, lines 20-22.
28	page 3, lines 16-21; page 19, lines 15-16.
29	page 3, lines 16-21 and 26-27; page 19, lines 13-14.
30	page 11, lines 19-21.
31	page 3, lines 11-12 and 23-25; page 8, lines 23-26; page 9, line 17 to page 12, line 28; page 12, lines 21-23.
32	page 9, lines 17-19; page 10, lines 1-4; page 11, lines 7-14 and 23-26.
33	page 3, lines 13-15; page 8, lines 6-12, 18-19 and 27-28; page 12, lines 17-19.
34	page 3, lines 17-19.
35	page 3, lines 19-21.
36	page 3, lines 26-27; page 12, lines 1-11; page 19, lines 20-21.
37	page 3, lines 16-21 and 26-27; page 10, line 22 to page 11, line 22; page 19, lines 11-12 and 13-14.
38	page 11, lines 19-21.
39	page 3, lines 11-12 and 23-25; page 8, lines 23-26; page 9, line 17 to page 12, line 28; page 12, lines 21-23.
40	page 9, lines 17-19; page 10, lines 1-4; page 11, lines 7-14 and 23-26.
41	page 3, lines 13-15; page 8, lines 6-12, 18-19 and 27-28; page 12, lines 17-19.
42	page 3, lines 17-19.
43	page 3, lines 19-21.

09/560,887

Claim	Location of Support in Specification
44	page 3, lines 26-27; page 12, lines 1-11; page 19, lines 20-22.
45	page 3, lines 16-21 and 26-27; page 10, line 22 to page 11, line 22; page 19, lines 11-14.
46	page 11, lines 19-21.

These changes are believed to introduce no new matter, and their entry is respectfully requested.

Summary

Applicants believe that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Heidi Kraus 29,021

Heidi L. Kraus
Attorney for Applicant
Registration No. 43,730

Date: 10-10-01

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

JAG/HLK

100101-24022600

Version with markings to show changes made

In the Claims:

The following claims 3-5 have been substituted for currently pending claims 3-5:

3. (Once amended) The method of claim [2] 1, further comprising administering to said patient Vitamin B12 [supplement].

4. (Once amended) The method of claim [2] 1, wherein the clioquinol is administered intermittently.

5. (Once amended) The method of claim [2] 1, wherein the clioquinol is administered orally.

The following claims 8-11 have been substituted for currently pending claims 8-11:

8. (Once amended) The method of claim [2] 1, further comprising administering trace metals with or subsequent to the administration of the clioquinol.

9. (Once amended) The method of claim [2] 1, wherein the clioquinol is administered [parenterally] parenterally.

10. (Once amended) The method of claim [2] 1, wherein the clioquinol is administered
[intradermaly] intradermally.

11. (Once amended) The method of claim [2] 1, wherein the therapy is carried out up
to 10 years.

Claim 2 has been canceled.

Claims 12-46 have been added.

FOOTNOTES